{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhao T"],"funding":["NCI NIH HHS","Chordoma Foundation"],"pagination":["72-83"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9534552"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["255(1)"],"pubmed_abstract":["Chordomas are primary bone tumors that arise in the cranial base, mobile spine, and sacrococcygeal region, affecting patients of all ages. Currently, there are no approved agents for chordoma patients. Here, we evaluated the anti-tumor efficacy of small molecule inhibitors that target oncogenic pathways in chordoma, as single agents and in combination, to identify novel therapeutic approaches with the greatest translational potential. A panel of small molecule compounds was screened in vivo against patient-derived xenograft (PDX) models of chordoma, and potentially synergistic combinations were further evaluated using chordoma cell lines and xenograft models. Among the tested agents, inhibitors of EGFR (BIBX 1382, erlotinib, and afatinib), c-MET (crizotinib), and mTOR (AZD8055) significant"],"journal":["The Journal of pathology"],"pubmed_title":["AZD8055 enhances in vivo efficacy of afatinib in chordomas."],"pmcid":["PMC9534552"],"funding_grant_id":["U01 CA231776"],"pubmed_authors":["Ji C","Williamson T","Burger PC","Cottone L","Zhang H","Zhao T","Ruzevick J","Connis N","Xia M","Hann CL","Siu IM","Flanagan AM","Gallia GL"],"additional_accession":[]},"is_claimable":false,"name":"AZD8055 enhances in vivo efficacy of afatinib in chordomas.","description":"Chordomas are primary bone tumors that arise in the cranial base, mobile spine, and sacrococcygeal region, affecting patients of all ages. Currently, there are no approved agents for chordoma patients. Here, we evaluated the anti-tumor efficacy of small molecule inhibitors that target oncogenic pathways in chordoma, as single agents and in combination, to identify novel therapeutic approaches with the greatest translational potential. A panel of small molecule compounds was screened in vivo against patient-derived xenograft (PDX) models of chordoma, and potentially synergistic combinations were further evaluated using chordoma cell lines and xenograft models. Among the tested agents, inhibitors of EGFR (BIBX 1382, erlotinib, and afatinib), c-MET (crizotinib), and mTOR (AZD8055) significant","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-26T15:32:40.384Z","creation":"2024-11-11T20:01:18.255Z"},"accession":"S-EPMC9534552","cross_references":{"pubmed":["34124783"],"doi":["10.1002/path.5739"]}}